Bayview Acquisition Corp
Bayview Acquisition Corp (BAYA/BAYAU/BAYAR) filed an 8-K under Item 3.01 disclosing that on October 30, 2026, Nasdaq's board of directors declined to review the Listing and Hearing Review Council's decisions. Those decisions had affirmed a June 19, 2026 deadline to complete the business combination with Oabay Inc. and a subsequent trading suspension. Nasdaq will now proceed to remove the company's securities from listing, with a Form 25-NSE expected but not yet filed. The company is seeking quotation on OTC Pink Market via a Form 211 filed September 16, 2026.
- Nasdaq board declined review on October 30, 2026, clearing the way for delisting.
- June 19, 2026 deadline to complete the Oabay Inc. business combination was not met.
- Nasdaq will file Form 25-NSE to remove securities from listing and registration.
- Company's market maker filed Form 211 with FINRA on September 16, 2026 for OTC Pink quotation.
- Securities affected: units (BAYAU), ordinary shares (BAYA), and rights (BAYAR).
Price data unavailable.
A SPAC losing its Nasdaq listing signals a failed business combination and forces shareholders into less liquid OTC trading.
This is a SPAC that failed to complete its de-SPAC transaction by its deadline, a common outcome in the post-2021 SPAC wave as many blank-check companies liquidate or move to OTC.
Delisting from Nasdaq removes exchange liquidity and could impair the company's ability to complete the Oabay business combination or raise capital. OTC Pink quotation is not assured and depends on FINRA approval.